S11 Table. Multivariable models for effect of primaquine on the rate of *P. vivax* recurrence between days 7 and 63 in patients receiving dihydroartemisinin-piperaquine

| | Total N (n)a | Adjusted HR (95% CI) | p value |
|--|--------------|----------------------|---------|
| Primaquine | | | |
| No | 341 (133) | Reference | - |
| Yes | 221 (2) | 0.06 (0.01, 0.63) | 0.0196 |
| Piperaquine dose, per every 5 mg/kg increase | 562 (135) | 0.76 (0.65, 0.88) | 0.0002 |
| Age, per every 5 year increase | 562 (135) | 0.99 (0.98, 1.01) | 0.2781 |
| Gender | | | |
| Male | 309 (98) | Reference | - |
| Female | 253 (37) | 0.67 (0.45, 1.01) | 0.0567 |
| Parasitaemia, parasites per μL every ten-fold increase | 562 (135) | 1.42 (1.07, 1.87) | 0.0151 |
| Baseline haemoglobin, per 1 g/dL increase | 562 (135) | 0.95 (0.86, 1.05) | 0.3605 |
| Relapse periodicity | | | |
| Long | 0 (0) | Reference | - |
| Short | 562 (135) | - | - |

HR – hazard ratio. CI = Confidence Interval.

^a Number of patients (number with recurrence by day 63). Only includes studies where patients followed for 63 days or longer. No patients from regions of long relapse periodicity were available for inclusion.

Theta (variance of frailty parameter for clustering of study sites) = 1.17.

The assumption of proportional hazards held by visual inspection.